BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 18851790)

  • 1. [Efficacy of chemotherapy combined hyperfractionated accelerated radiotherapy on limited small cell lung cancer].
    Hu X; Bao Y; Chen YY; Gao JM; Wang WH; Liu Y; He H; Sun ZW; Poudel S; Wang Y; Zhuang TT; Zhang L; Chen M
    Ai Zheng; 2008 Oct; 27(10):1088-93. PubMed ID: 18851790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
    Dong XJ; Wang MZ; Zhong W; Zhang L; Zhang XT; Zhao J; Xia Y; Li LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):216-21. PubMed ID: 22780978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
    Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation 
with Concurrent Twice-daily Radiotherapy for Patients 
with Limited-stage Small Cell Lung Cancer].
    You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
    Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):55-60. PubMed ID: 28103974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
    Ariyoshi Y; Fukuoka M; Furuse K; Saijo N; Ikegami H; Nishiwaki Y; Tamura T; Shimoyama M; Suemasu K
    Jpn J Clin Oncol; 1994 Oct; 24(5):275-81. PubMed ID: 7967106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-year results of a phase II trial of hyperfractionated radiotherapy and concurrent daily cisplatin chemotherapy for stage III non-small-cell lung cancer.
    Keene KS; Harman EM; Knauf DG; McCarley D; Zlotecki RA
    Am J Clin Oncol; 2005 Jun; 28(3):217-22. PubMed ID: 15923791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer.
    Rwigema JM; Verma V; Lin L; Berman AT; Levin WP; Evans TL; Aggarwal C; Rengan R; Langer C; Cohen RB; Simone CB
    Cancer; 2017 Nov; 123(21):4244-4251. PubMed ID: 28678434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 study of accelerated hypofractionated thoracic radiation therapy and concurrent chemotherapy in patients with limited-stage small-cell lung cancer.
    Xia B; Hong LZ; Cai XW; Zhu ZF; Liu Q; Zhao KL; Fan M; Mao JF; Yang HJ; Wu KL; Fu XL
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):517-23. PubMed ID: 25481679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer.
    Belani CP; Wang W; Johnson DH; Wagner H; Schiller J; Veeder M; Mehta M;
    J Clin Oncol; 2005 Jun; 23(16):3760-7. PubMed ID: 15837967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study.
    Xenidis N; Kotsakis A; Kalykaki A; Christophyllakis Ch; Giassas S; Kentepozidis N; Polyzos A; Chelis L; Vardakis N; Vamvakas L; Georgoulias V; Kakolyris S
    Lung Cancer; 2010 Jun; 68(3):450-4. PubMed ID: 19783319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
    J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: results of radiation therapy oncology group trial 93-12.
    Glisson B; Scott C; Komaki R; Movsas B; Wagner H
    J Clin Oncol; 2000 Aug; 18(16):2990-5. PubMed ID: 10944132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trial of post-chemotherapy consolidation thoracic radiotherapy for extensive-stage small cell lung cancer.
    Yee D; Butts C; Reiman A; Joy A; Smylie M; Fenton D; Chu Q; Hanson J; Roa W
    Radiother Oncol; 2012 Feb; 102(2):234-8. PubMed ID: 21930323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer.
    Komaki R; Shin DM; Glisson BS; Fossella FV; Murphy WK; Garden AS; Oswald MJ; Hong WK; Roth JA; Peters LJ
    Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):807-11. PubMed ID: 7860392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accelerated hyperfractionated radiotherapy and concomitant chemotherapy in small cell lung cancer limited-disease. Dose response, feasibility and outcome for patients treated in western Sweden, 1998-2004.
    Hallqvist A; Rylander H; Björk-Eriksson T; Nyman J
    Acta Oncol; 2007; 46(7):969-74. PubMed ID: 17851846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Concurrent chemoradiation with paclitaxel and platinum for locally advanced esophageal cancer].
    Zhang P; Xie CY; Wu SX
    Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):773-7. PubMed ID: 18396692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of split-dose cisplatin and etoposide with concurrent accelerated hyperfractionated thoracic radiotherapy in elderly patients with limited-disease small cell lung cancer.
    Okamoto K; Okamoto I; Takeda M; Kobayashi S; Takeda K; Nakamatsu K; Nishimura Y; Nakagawa K
    Jpn J Clin Oncol; 2014 Aug; 44(8):743-8. PubMed ID: 24868080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of hyperfractionated accelerated radiotherapy (HART) after induction cisplatin (CDDP) and vinorelbine (VNR) for stage III non-small-cell lung cancer (NSCLC).
    Ishikura S; Ohe Y; Nihei K; Kubota K; Kakinuma R; Ohmatsu H; Goto K; Niho S; Nishiwaki Y; Ogino T
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1117-22. PubMed ID: 15752891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma.
    Kakolyris S; Agelidou A; Androulakis N; Tsaroucha E; Kouroussis Ch; Agelidou M; Karvounis N; Veslemes M; Christophylakis Ch; Argyraki A; Geroyianni A; Georgoulias V
    Lung Cancer; 2006 Jul; 53(1):59-65. PubMed ID: 16716447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phase II clinical trial of concurrent chemoradiotherapy (cisplatin plus 5-fluorouracil) for esophageal cancer].
    Lin Q; Gao XS; Qiao XY; Chen K; Wang YD; Zhou ZG
    Ai Zheng; 2008 Oct; 27(10):1077-81. PubMed ID: 18851788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.